Representative Image: Reuters
Pfizer Inc said Tuesday that participants showed mild to moderate side effects when given the company’s experimental coronavirus vaccine or a placebo in an ongoing late-stage study.
- Reuters
- Last update: September 16, 2020 8:35 AM M. IST
- FOLLOW US:
Pfizer Inc said Tuesday that participants showed mild to moderate side effects when given the company’s experimental coronavirus vaccine or a placebo in an ongoing late-stage study.
More than 12,000 study participants had received a second dose of the vaccine, Pfizer executives said in a conference call with investors.
The company has enrolled more than 29,000 people in its 44,000-volunteer trial to test the experimental COVID-19 vaccine it is developing with German partner BioNTech.
Pfizer said it was continually examining the safety and tolerability of the vaccine in its study.
An independent data monitoring committee could recommend pausing the study at any time, but has not done so to date, the company said.
The comments follow rival AstraZeneca’s COVID-19 vaccine trials that were suspended worldwide on September 6 after a serious side effect was reported in a volunteer in Britain.
AstraZeneca trials resumed in Britain and Brazil on Monday after the green light from British regulators, but remain on hold in the United States.
.
